ClinicalTrials.gg
RecruitingNCT07507838Updated Jul 14, 2026

Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV913 Capsules

An Early Phase 1 interventional study of VV913 4mg group and VV913 8mg group in Healthy Volunteers, sponsored by Vigonvita Life Sciences. Recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Vigonvita Life Sciences · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This study is a single-center, randomized, double-blind, placebo-controlled, dose-escalation trial to assess the safety, tolerability, pharmacokinetics (PK) of multiple doses of VV913 in Chinese healthy adult participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Vigonvita Life Sciences is the lead sponsor of 39 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 45 years old, males ;
  2. Males weight no less than 50 kg, with of 19 to 26 kg/m\^2;
  3. Vital signs examination, physical examination, laboratory examination ,Chest X-ray are normal or considered abnormal without clinical significance by the investigator;
  4. Participants who are willing to take proper methods during the study and within 3 months after the the last administration;
  5. Participants who are able to understand and follow the study protocol and instructions; participants who have voluntarily decided to participate in this study, and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Participants with to preparation or any of the ;
  2. Participants with allergic constitution (such as asthma, urticaria, eczematous dermatitis and other allergic diseases), or have a history of drug or food allergy;
  3. Participants with central nervous system, cardiovascular system, gastrointestinal, respiratory system, urinary, hematologic, or metabolic disorders that require medical intervention or other diseases (such as psychiatric history) that are not suitable for clinical trials; Participants with a history of gastrointestinal conditions that may impair drug absorption (e.g., gastrectomy or small intestine resection, atrophic gastritis, gastrointestinal ulcers or perforations/fistulas, gastrointestinal bleeding, or obstruction);
  4. Participants with a history of surgery within 3 months before screening, or have not recovered from surgery, or have an expected surgical plan during the trial;
  5. Participants with a blood donation or blood loss ≥ 400 mL within 3 months before screening, or a history of blood product use within 3 months before screening;
  6. Participating in any clinical trial and taking clinical trial drugs within 90 days before screening;
  7. Participants who have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 14 days before screening;
  8. Participants who have received vaccination within 14 days before screening, or planned to receive any vaccine during the trial or within 1 week after the end of the study;
  9. Participants with a history of drug abuse within 1 year before screening or positive urine drug screening within 1 year before screening results (morphine, tetrahydrocannabinol, methamphetamine, dimethylene diphenazine , ketamine, and cocaine);
  10. Participants who drink more than 14 standard units or at least twice a day per week within one year before screening (one standard unit equals 200 mL of beer with 5% alcohol or 25 mL of spirits with 40% alcohol content or 85 mL of wine with 12% alcohol content);
  11. Participants who smoke more than 5 cigarettes a day within one year before screening;
  12. Participants who can't quit smoking or drinking during the trial period;
  13. Participants who are positive for virus surface antigen, virus antibody, treponema pallidum antibody or antibody (Anti-HIV);
  14. Having special requirements for food, unable to observe a unified diet or having dysphagia;
  15. Participants who cannot avoid consuming drinks containing xanthine (such as coffee and tea) or foods (such as chocolate and animal liver), or fruits or juices (such as grapefruit, pomelo, mango, and dragon fruit) that may affect drug metabolism,from 48 hours before administration until the end of the study;
  16. Participants who cannot tolerate blood collection with intravenous indwelling needles or blood fainting;
  17. Participants with difficulty in swallowing capsules;
  18. Participants whose female partners plan to conceive within 3 months;
  19. The investigator believes that there are other unsuitable factors to participate this trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    VV913

    Drug: VV913 4mg group · Drug: VV913 8mg group · Drug: VV913 15mg group

  • Placebo comparator
    Placebo

    Drug: VV913 4mg group · Drug: VV913 8mg group · Drug: VV913 15mg group

Interventions

  • 6 participants will receive VV913 4mg orally; 2 participants will receive placebo orally.

  • 6 participants will receive VV913 8mg orally; 2 participants will receive placebo orally.

  • 6 participants will receive VV913 15mg orally; 2 participants will receive placebo orally.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Incidence of Treatment-Emergent Adverse Events

    Time frame: Baseline to 6 days after the last administration

  2. Cmax

    maximum observed plasma concentration

    Time frame: Baseline to 72 hours after the last administration

  3. AUC0-∞

    area under the plasma concentration time curve from time zero to infinity

    Time frame: Baseline to 72 hours after the last administration

  4. Tmax

    time at which Cmax occurs

    Time frame: Baseline to 72 hours after the last administration

  5. t1/2

    half-life of elimination

    Time frame: Baseline to 72 hours after the last administration

  6. Apparent Clearance Rate(CL/F)

    apparent clearance

    Time frame: Baseline to 72 hours after the last administration

  7. Vd/F

    apparent volume of distribution during the terminal phase

    Time frame: Baseline to 72 hours after the last administration

  8. λz

    elimination rate constant

    Time frame: Baseline to 72 hours after the last administration

  9. AUC0-24h

    area under the plasma concentration time curve from time zero to 24h

    Time frame: Baseline to 72 hours after the last administration

  10. mean Resident Time

    mean Resident Time from time zero to infinity/the last

    Time frame: Baseline to 72 hours after the last administration

  11. Rac

    Accumulation Ratio of VV913

    Time frame: Baseline to 72 hours after the last administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2026
First posted
Apr 2, 2026
StartActual
Apr 13, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07507838
Responsible party
Sponsor
First posted
Apr 2, 2026
Start date
Apr 13, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 14, 2026

Study contacts

Huaqing Duan
Contact
huaqing.duan@vigonvita.cn
18061926005
Huan Zhou
principal investigator · The First Affiliated Hospital of Anhui Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VV913

Start the discussion